保灵药业品牌怎么样 申请店铺

我要投票 保灵药业在中草药行业中的票数:36 更新时间:2024-12-27
保灵药业是哪个国家的品牌?「保灵药业」是 杭州澳医保灵药业有限公司 旗下著名品牌。该品牌发源于浙江,由创始人钟海荣在1994-12-30期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
保灵药业怎么样

杭州保灵集团有限公司,成立于1985年,是国内较早从事蜂产品深度研究开发生产的企业。2013年8月,保灵集团正式牵手山西仟源制药股份有限公司。

澳医保灵成立于1994年,由保灵集团与澳大利亚、新加坡合资组建,注册资本为2882.47万元,位于杭州市保灵路5号,主要经营药品与原料药的生产工作。先后被评为杭州市高新技术企业及浙江省高新技术企业。

浙江保灵成立于2006年,由保灵集团与爱美雅(新加坡)有限公司合资组建,注册资本为8800万元,位于杭州经济技术开发区23号大街668号。一期总投资1.6亿元的现代化药品保健食品制造基地,于2010年12月投产。2013年12月,澳医保灵吸收合并浙江保灵。吸收合并后,浙江保灵于工商注销,澳医保灵注册资本为8800万元,注册地址为杭州经济技术开发区23号大街668号。

保灵药业主要从事药品、保健食品、蜂产品、植物提取物的研发、生产和销售。公司是国内著名的孕妇健康产品生产商和供应商,其系列产品包括保灵孕宝口服液、保灵孕妇钙咀嚼片、保灵孕多维片以及保胎无忧片、生乳片等,其中保灵孕宝口服液自1989年(与澳方合资前由中方公司生产)上市以来,深受广大医生和孕妇的喜爱,“怀孕了就喝保灵孕宝”,“保灵孕宝健康两代人”已经深入人心。公司还拥有抗过敏药物,国家二类新药---依巴斯汀片(商品名“思金”),治疗青光眼药物---醋甲唑胺片(商品名“尼目克司”)等市场优势品种。自1997年以来,“保灵”商标就被评为浙江省著名商标。

保灵药业视产品质量为企业的立足之本,更是企业对社会的一种责任。公司每年按销售额的一定比例拨出专项资金作为技术改造及新产品研发费用,不断引进国内外领先的先进生产研发设备,如高效液相色谱仪、红外分光光度计等等,提高工作效率,改善生产条件,确保了产品质量安全稳定。保灵药业是浙江省首批通过药品和保健食品GMP双认证的企业。

保灵药业拥有一支高素质的员工队伍。在现有员工中,各类专业技术人员的比例超过40%。公司非常重视企业文化建设,不断引进现代企业管理理念和方法。培育了“效率、效益、和谐发展”为特质的保灵文化,培养了具有“忠诚、友善、敬业、创新”精神的保灵人。在和谐的保灵大家庭中,广大员工视公司为家,涌现了包括全国劳模、省劳模在内的一大批优秀人才。近年来,公司先后被评为浙江省文明单位、杭州市模范集体、杭州市和谐劳动关系先进企业、浙江省先进技术企业,浙江省高新技术企业,省级研发中心,杭州市工业重点纳税企业。

Hangzhou Baoling Group Co., Ltd., founded in 1985, is one of the earliest domestic enterprises engaged in the in-depth research, development and production of bee products. In August 2013, Baoling group formally joined hands with Shanxi Qianyuan Pharmaceutical Co., Ltd. Founded in 1994 by Baoling group, Australia and Singapore, aowuling has a registered capital of 28.8247 million yuan and is located at No.5, Baoling Road, Hangzhou, mainly engaged in the production of drugs and APIs. It has been awarded as Hangzhou high tech enterprise and Zhejiang high tech enterprise successively. Zhejiang Baoling was founded in 2006 by Baoling group and aimiya (Singapore) Co., Ltd. with a registered capital of 88 million yuan, it is located at No. 668, No. 23 street, Hangzhou Economic and Technological Development Zone. The first phase of a modern pharmaceutical and health food manufacturing base with a total investment of 160 million yuan was put into production in December 2010. In December 2013, aomaling absorbed and merged with Zhejiang Baoling. After the merger, Zhejiang Baoling was cancelled by industry and commerce. The registered capital of aobaoling is 88 million yuan, and the registered address is No. 668, No. 23 street, Hangzhou Economic and Technological Development Zone. Baoling pharmaceutical is mainly engaged in the R & D, production and sales of drugs, health food, bee products and plant extracts. The company is a famous manufacturer and supplier of pregnant women's health products in China. Its series of products include baolingyunbao oral liquid, Baoling pregnant women's calcium chewable tablets, baolingyun multi-dimensional tablets, baofetal worry free tablets, raw milk tablets, etc., among which baolingyunbao oral liquid has been popular with doctors and pregnant women since it was launched in 1989 (before the joint venture with Australia, it was produced by a Chinese company), and "drink when pregnant" "Baoling pregnant treasure" and "Baoling pregnant treasure healthy two generations" have been deeply rooted in people's hearts. The company also has anti allergy drugs, national class II new drugs - ebastine tablets (trade name "sikin"), glaucoma drugs - acetazolamide tablets (trade name "nemex") and other market advantages. Since 1997, "Baoling" trademark has been awarded as a famous trademark in Zhejiang Province. Baoling pharmaceutical regards product quality as the foundation of the enterprise, and it is also a responsibility of the enterprise to the society. According to a certain proportion of the sales volume, the company allocates special funds every year as the cost of technological transformation and new product research and development, and constantly introduces advanced production and research and development equipment at home and abroad, such as high-performance liquid chromatograph, infrared spectrophotometer, etc., to improve work efficiency, improve production conditions, and ensure the safety and stability of product quality. Baoling pharmaceutical is one of the first enterprises in Zhejiang Province to pass the GMP double certification of drugs and health food. Baoling pharmaceutical has a high-quality staff. In the existing staff, the proportion of all kinds of professional and technical personnel is more than 40%. The company attaches great importance to the construction of enterprise culture and constantly introduces modern enterprise management concepts and methods. It has cultivated a spirit preserving culture characterized by "efficiency, efficiency and harmonious development", and a spirit of "loyalty, friendliness, dedication and innovation". In the harmonious Baoling family, the majority of employees regard the company as their home, and a large number of outstanding talents including national and provincial model workers have emerged. In recent years, the company has been rated as a civilized unit in Zhejiang Province, a model collective in Hangzhou, an advanced enterprise in harmonious labor relations in Hangzhou, an advanced technology enterprise in Zhejiang Province, a high-tech enterprise in Zhejiang Province, a provincial R & D center, and a key industrial tax paying enterprise in Hangzhou.

本文链接: https://brand.waitui.com/940fa6127.html 联系电话:057188144888

千城特选小程序码

7×24h 快讯

沪深两市成交额连续第63个交易日突破1万亿

36氪获悉,沪深两市成交额连续第63个交易日突破1万亿,较上日此时放量近1100亿。

2小时前

日本政府通过温室气体减排新目标:2035年度较2013年度减排60%

据报道,日本政府12月27日召开全球变暖对策推进总部(总部长:首相石破茂)会议,通过了全球变暖对策计划的修改方案,其中提出“2035年度较2013年度减排60%、2040年度减排73%”的温室气体减排新目标。日本政府将在征求公众意见后,在内阁会议上敲定修改方案,并力争在2025年2月底前向联合国汇报。(界面)

2小时前

南京公用宣布并购,股价“提前”涨停,公司最新回应

26日晚间,南京公用公告,公司拟购买宇谷科技约68%股权并募集配套资金。本次交易预计不构成重大资产重组,不构成重组上市。公司股票自12月27日开市起停牌,预计不超过10个交易日。公告当日,该股录得涨停。对此,南京公用相关人士表示,公司主营能源业务,以传统燃气为主。同时也在布局新能源领域,包括充电桩业务等,不过体量尚小。目前相关事宜处于初步商谈阶段,后续情况以公司公告为准。关于股价“提前”涨停,前述人士表示,公司股价近期涨跌频繁,不清楚昨日涨停原因。交易双方不存在内幕消息泄露的情形。(21财经)

2小时前

力箭一号遥六民营商业运载火箭飞行试验任务失利

12月27日9时3分,力箭一号遥六民营商业运载火箭在东风商业航天创新试验区点火升空,火箭飞行异常,飞行试验任务失利。具体原因正在进一步分析排查。(新华社)

2小时前

韩国央行:超三成韩国人持有加密货币

韩国央行根据在Upbit、Bithumb、Coin One、Cobit和Gopax等五大韩国交易所拥有账户的投资者数量统计发布报告称,截至今年11月,在韩国交易所持有加密货币的人数超过1559万人,比10月份的1498万人增加了61万人。目前,韩国总人口预计在5123万人左右。这意味着,持有加密货币的人口数量相当于总人口的30%以上。报告称,韩国加密货币投资者的数量一直在上升,而在11月更是直线飙升。(财联社)

2小时前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询